Drug intelligence / Profile preview

NK365

Development stage: Unknown
Lead developer: NKMax
Administration: Oral

Overview

NK365 is a multivitamin and mineral complex that includes Agaricus blazei powder. Developed by NKmax Co., Ltd., this complex is designed to exert immunomodulatory effects, primarily by stimulating natural killer (NK) cell proliferation and boosting their cytotoxicity. The bioactive constituents, particularly β-glucans from Agaricus blazei, are believed to activate macrophages and NK cells through binding to Dectin-1 and Complement receptor 3 (CR3). It has been investigated in a pilot clinical trial for its potential to enhance postoperative immune recovery in patients undergoing curative resection for non-small-cell lung cancer.

Brand names: NK365NK-365NK 365
Other names: multivitamin and mineral complex containing Agaricus blazei powder

Targets

CLEC7A (Dectin-1)αMβ2 (Integrin αMβ2)

Beyond the preview

Go deeper on NK365.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NK365.

Explore the full profile